# Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

> **NCT05524974** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Medical University** · enrollment: 203 (estimated)

## Conditions studied

- Locally Advanced Gastric Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Oxaliplatin
- **DRUG:** S1
- **DRUG:** Apatinib Mesylate
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT05524974
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-09-01
- **Primary completion:** 2024-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 203 (ESTIMATED)
- **Last updated:** 2022-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05524974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05524974, "Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05524974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*